title: Twenty-four-hour intragastric pH patterns in ICU patients on ranitidine.
abstract: Thirty critically ill patients with mixed diagnoses underwent continuous intragastric pH monitoring for 72 hr while confined to a shock/trauma intensive care unit. The first 24 hr were monitored under no specific acid-suppressing therapy (placebo control). During the second and third consecutive 24-hr periods, patients received continuous infusion of intravenous ranitidine in the dose of 6.25 mg/hr and 12.5 mg/hr, respectively. Results of the placebo-control 24-hr study revealed that one third (N = 10) of the patients were gastric acid hyposecretors (24-hr median intragastric pH values above pH 4.0). In the normosecreting group (N = 20), both ranitidine schedules significantly elevated 24-hr median pH values, when compared to placebo (placebo 24-hr median intragastric pH 1.75; ranitidine 6.25 mg/hr 24-hr median intragastric pH 4.625, P < 0.0001; ranitidine 12.5 mg/hr 24-hr median intragastric pH 6.29, P = 0.0099). Five patients (18%) failed to adequately respond to the ranitidine 12.5 mg/hr dose (24-hr median intragastric pH < 4.0). These findings suggest that a significant percentage of intensive care unit patients are not in need of acid-suppressing therapy as prophylaxis against stress-induced ulceration. Conversely, other patients may require more intensive acid-suppressing regimens because of failure to respond to high dose H2-antagonist therapy.
authors: Department of Medicine, LDS Hospital, University of Utah School of Medicine, Salt Lake City.
authors: J G
authors: JG
authors: Moore
authors: T P
authors: TP
authors: Clemmer
authors: S
authors: S
authors: Taylor
authors: A L
authors: AL
authors: Bishop
authors: S
authors: S
authors: Maggio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002940:Circadian Rhythm; D005260:Female; D005745:Gastric Acidity Determination; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D010437:Peptic Ulcer / Q000209:etiology / Q000517:prevention & control; D011899:Ranitidine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013312:Stress, Physiological / Q000150:complications
chemical_list: D011899:Ranitidine